Follow The Filings

CLDX Celldex Therapeutics Inc.

Health Care, filed as CELLDEX THERAPEUTICS INC NEW (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 2 Owners
  • Max 2.1%
  • $17M
  • 1 add

In 2026 Q2 Palo Alto Investors added to Celldex Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 2.1% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors Add 2.1%
  2. Nathan Fischel 0.49%

Who owns CLDX

Sorted by value, long equity only, as of 2026 Q2.

History
Palo Alto Investors 2.1%, was 1.4% Add +34.9% 399,856 $15M History
Nathan Fischel, Dafna Capital Management 0.49% Hold 68,518 $2.6M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by CLDX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CLDX insider trades
  • None no insider bought on the open market
  • $1.3M sold by 2 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Freddy A. Jimenez SVP & General Counsel
    Sale
    $121K 4,166 shares at $29.10 12% of stake
    Traded Dec 4, 2025 Filed Dec 8, 2025
    ↗
  2. Richard M. Wright Insider
    Sale
    $1.2M 49,298 shares at $24.00 70% of stake
    Traded Nov 13, 2025 Filed Nov 17, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 6 option exercises.

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A FORM DEF 14A Filing Doc
SCHEDULE 13G — Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-K Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $6.88M $7.02M $1.54M
Gross profit * $6.58M $6.82M $1.34M
Gross margin * 95.6% 97.2% 87.1%
Net income — — -$258.76M
Net margin * — — -16748.0%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $431.69M $747.16M $534.66M
Total non-current assets * $33.93M $45.18M $48.32M
Total assets $465.63M $792.34M $582.98M
Total current liabilities $31.12M $39.5M $50.99M
Total non-current liabilities * $5.33M $5.83M $4.83M
Total equity $429.17M $747M $527.16M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$107.29M -$157.78M -$210.94M
Cash from investing -$105.78M -$290.13M $209.07M
Cash from financing $218.46M $441.45M $2.39M
Net change in cash $5.38M -$6.46M $0.515M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.